Follow
TCR-engineering Cell Therapy
T cell receptor (TCR) engineering cell therapy is a form of T cell engineering using T cells obtained from a patient. Once harvested, T cells are modified in a laboratory setting. T cells are engineered to express a TCR that recognizes major histocompatibility complex (MHC) proteins on tumor cells. Engagement of a TCR and MHC molecule initiates the anti-tumor immune response.
MAY 31, 2022 | 9:00 AM
Date: May 31, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Introducing Nanostring’s latest spatial platform, CosMx Spatial Molecular Imager (SMI). Offering high-plex, multiomi...
DEC 09, 2021 | 8:00 AM
Date: December 9, 2021 Time: 8:00am (PDT), 11:00am (EDT) Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donorderived human leukocyte antigen (H...
JUL 22, 2021 | 5:00 PM
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
JUL 22, 2021 | 4:15 PM
Genome editing technologies have enabled the precise manipulation of DNA sequences at targeted sites to achieve therapeutic effects. Engineered endonucleases like CRISPR-Cas9 institute site-...
JUL 22, 2021 | 12:00 PM
T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral...
JUN 02, 2021 | 12:00 AM
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
AUG 04, 2020 | 8:00 AM
DATE: June 23, 2020 TIME: 6:00 am PDT, 9:00 am EDT In this webinar for scientists and researchers, Rama Shivakumar, a senior scientist at MaxCyte Inc., will highlight powerful case studies t...
JUL 29, 2020 | 9:00 AM
Advances in genetic engineering have improved specificity, safety and potency of T-cell receptor (TCR) and Chimeric Antigen Receptor (CAR-T) based therapies for solid and non-solid tumours....